贝伐单抗联合化疗治疗晚期乳腺癌的临床研究

Effect of Bevacizumab combined with chemotherapy on patients with advanced breast cancer

目的分析贝伐单抗联合化疗在晚期乳腺癌患者中的应用价值。方法选择在该院接受住院治疗的晚期乳腺癌患者作为研究对象,随机分为单独接受化疗的对照组以及接受贝伐单抗联合化疗的观察组,比较两组患者的治疗效果以及Th1及Th2细胞因子含量和血管内皮生长因子(VEGF)水平等差异。结果观察组患者接受贝伐单抗联合化疗后的完全缓解(CR)及部分缓解(PR)率明显高于对照组、疾病稳定(SD)及疾病进展(PD)率低于对照组(P<0.05)。观察组患者接受贝伐单抗联合化疗后的血清Th1细胞因子水平高于对照组,Th2细胞因子低于对照组(P<0.05)。观察组患者接受治疗后的VEGFA、VEGFB和VEGFC水平明显低于对照组患者(P<0.05)。结论贝伐单抗联合化疗可以有效提升晚期乳腺癌患者的治疗效果,优化Th1及Th2细胞因子水平,降低血清VEGF水平。

【Objective】 To analyze the effect of Bevacizumab combined with chemotherapy on patients with advanced breast cancer. 【Methods】Eighty-six patients with advanced breast cancer in our hospital were choosed as the research objects, and were randomly divided into control group with chemotherapy alone and observation group with Bevacizumab combined with chemotherapy. The treatment effect and Th1 and Th2 cytokines content, serum VEGF levels in two groups were compared. 【Results】The CR and PR rates of observation group were significantly higher than those of control group, but SD and PD rates were significantly lower（P〈0.05）. The serum levels of Th1 cytokine in observation group were higher than those in control group, while levels of Th2 cytokines were lower（P〈0.05）. The serum VEGFA, VEGFB, VEGFC levels in observation group were significantly lower than those in control group（P〈0.05）. 【Conclusion】Bevacizumab combined with chemotherapy can enhance the treatment effect for advanced breast cancer, optimize the levels of Th1 and Th2 cytokines, and reduce the serum VEGF levels.